CCCCNasdaq

C4 Therapeutics, Inc.

Alert me on CCCC

Insider buys, 6 months

Congress trades, 6 months

Signals, 6 months

Six months

After each filing

Jan 17 Sale REYNO LEONARD Insider

1 week

−1.8%S&P +2.6%

1 month

−2.8%S&P +1.0%

3 months

+43.1%S&P +4.2%

6 months

+71.6%S&P +10.9%

Every purchase and sale on this ticker reported by a member of Congress or an insider, measured from the close of the first trading day after it became public to the close 1 week, 1 month, 3 months and 6 months later, each beside the S&P over the same days.

Filings for CCCC

55 held · newest 555 held · newest 2

Loading the filings.

See all 55 filings for CCCC

Aeon news and offers by email

New sources, new features and offers like our founding price. A few times a month at most. Stop any time.

Signal history

No signal for this ticker yet. A signal is written when insider buying here scores one dot or more.

Stakes

Jun 30, 2026 Schedule 13G, amended

RA Capital Management, L.P.: 9.9%, 11,383,696 shares

Jun 30, 2026 Schedule 13G, amended

Lynx1 Capital Management LP: 10%, 15,423,691 shares

Jun 30, 2026 Schedule 13G, amended

Squadron Master Fund LP: 6.9%, 7,600,000 shares

Jun 30, 2026 Schedule 13G, amended

Morgan Stanley: 8%, 8,862,002 shares

Jun 30, 2026 Schedule 13G

BlackRock, Inc.: 6.9%, 7,678,906 shares

May 12, 2026 Schedule 13G

Squadron Master Fund LP: 5%, 5,550,000 shares

Mar 31, 2026 Schedule 13G, amended

Point72 Asset Management, L.P.: 0.2%, 169,096 shares

Mar 31, 2026 Schedule 13G

Sirenia Capital Management LP: 9.9%, 23,505,000 shares

Mar 31, 2026 Schedule 13G, amended

Wasatch Advisors LP: 4.7%, 4,581,761 shares

Dec 31, 2025 Schedule 13G, amended

OrbiMed Capital LLC: 1%, 883,534 shares

Dec 31, 2025 Schedule 13G, amended

Lynx1 Capital Management LP: 7.3%, 7,098,133 shares

Dec 31, 2025 Schedule 13G, amended

Soleus Capital Master Fund, L.P.: 10%, 10,361,860 shares

Dec 31, 2025 Schedule 13G, amended

Morgan Stanley: 9.3%, 8,974,191 shares

Sep 30, 2025 Schedule 13G, amended

OrbiMed Capital LLC: 5%, 3,568,346 shares

Sep 30, 2025 Schedule 13G, amended

Wasatch Advisors LP: 6.8%, 4,852,741 shares

Oct 17, 2025 Schedule 13G

BCLS II Equity Opportunities, LP: 6.3%, 6,060,000 shares

Oct 17, 2025 Schedule 13G

RA Capital Management, L.P.: 9.9%, 9,441,256 shares

Oct 17, 2025 Schedule 13G

Point72 Asset Management, L.P.: 9.9%, 22,647,647 shares

Schedule 13D is filed within 5 business days of crossing 5 percent by an investor who may seek to influence the company. Schedule 13G is filed by a passive holder, and a large institution has up to 45 days after the quarter end.

Government contracts, last 12 months

Awards of $10M and up, from USAspending · context, not a signal

No contracts of $10M or more in the last 12 months.

Lobbying

Last four quarters

No lobbying reports on file.